Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

On Monday, Vertex Inc (VERX) stock saw a decline, ending the day at $49.29 which represents a decrease of $-2.70 or -5.19% from the prior close of $51.99. The stock opened at $50.35 and touched a low ...

Vertex Minerals Ltd. (AU:VTX) has released an update. Vertex Minerals Ltd. is advancing the redevelopment of the Reward Gold Mine with the ...

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Vertex currently has a Zacks Rank ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Vertex, Inc. VERX reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance on ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Downgrading Vertex to neutral due to limited upside at ... I had a price target of $46 when I wrote about VERX in August, and the stock price today is $49 (after the jump post 3Q24 results).

William Blair analyst Jake Roberge has maintained their bullish stance on VERX stock, giving a Buy rating today. Jake Roberge has given his ...

Bank of America reduced their price target on shares of Vertex Pharmaceuticals from $550.00 to $541.00 and set a “buy” rating on the stock in a research report on Monday, October 14th.

Finally, KBC Group NV raised its stake in Vertex by 46.1% during the 3rd quarter. KBC Group NV now owns 2,099 shares of the company’s stock worth $81,000 after acquiring an additional 662 shares ...

These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.